- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01505842
Chromoendoscopy for Dysplasia Detection in Chronic Inflammatory Bowel Disease
Randomized Controlled Trial (RCT) to Compare Dysplasia Detection Rate in Colonoscopy Without Chromoendoscopy Versus Colonoscopy With Chromoendoscopy in Detecting Dysplasia in Ulcerative Colitis and Crohn's Colitis Patients.
Study Overview
Status
Conditions
Detailed Description
Background: Patients with ulcerative colitis and Crohn's colitis are at increased risk of colon cancer. The usefulness of chromoendoscopy is debated. Previous studies are either based on magnifying endoscopy or on non-randomized trials. Some guidelines recommend chromoendoscopy with targeted biopsies and some normal colonoscopy with up to 40 random biopsies.
Chromoendoscopy has the ability to identify subtle lesions that are otherwise missed by standard endoscopy. Whether chromoendoscopy with targeted biopsies can replace standard colonoscopy with random biopsies in the surveillance of patients with chronic colitis is unknown.
Aim: In a RCT in surveillance colonoscopies in patients with ulcerative colitis or Crohn's colitis, we will determine if chromoendoscopy using a dilute solution of Indigo-carmine will improve dysplasia detection rate compared with colonoscopy without chromoendoscopy.
Methods: After informed consent patients undergoing surveillance colonoscopy will be randomized to be examined by the study or control method. The study method will employ a 0.2-0.5% Indigo-Carmine solution sprayed over the colonic and rectal mucosa. The control method will be colonoscopy without Indigo-Carmine chromoendoscopy. In both the study arm and the control arm all subjects will have 32 random biopsies taken (4 from each of 8 defined segments of the colon) and biopsies from suspicious mucosa.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Stockholm, Sweden, 17176
- Karoliniska University Hospital, Dept. of Gastroenterology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients with ulcerative colitis or Crohn's colitis satisfying criteria for surveillance colonoscopy:
- Ulcerative colitis, extensive > 8 years OR Crohn's colitis involving ≥ 1/3 of colon/rectum
- history of PSC or
- history of previous dysplasia on colon biopsies or
- family history of colon cancer in first degree relative
Exclusion Criteria:
- Patients who decline to participate
- Unable to give informed consent
- Increased risk of bleeding (i.e. Warfarin, bleeding disorders, Clopidogrel)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Colonoscopy with chromoendoscopy
Colonoscopy with chromoendoscopy using 0.2-0.5% Indigo-Carmine solution sprayed in the whole colon and rectum plus 32 random biopsies plus biopsies from suspicious areas
|
Colonoscopy with chromoendoscopy using 0.2-0.5% Indigo-Carmine solution sprayed in the whole colon and rectum plus 32 random biopsies plus biopsies from suspicious areas
Other Names:
|
|
ACTIVE_COMPARATOR: Conventional colonoscopy
White light colonoscopy plus 32 random biopsies plus biopsies from suspicious areas
|
White light colonoscopy plus 32 random biopsies plus biopsies from suspicious areas
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prevalence of dysplastic lesions
Time Frame: 12 month
|
Number of patients with dysplastic lesions by colonoscopy with chromoendoscopy using Indigo-carmine versus colonoscopy without chromoendoscopy
|
12 month
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number and rate of targeted and non-targeted biopsies detecting dysplasia and non-dysplasia
Time Frame: 12 month
|
12 month
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PTS-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ulcerative Colitis
-
Rise Therapeutics LLCUniversity of Colorado, Denver; Mayo ClinicRecruitingUlcerative Colitis | Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic | Ulcerative Colitis Chronic MildUnited States
-
Eli Lilly and CompanyRecruitingUlcerative Colitis, Active Severe | Ulcerative Colitis (UC) | Ulcerative Colitis, Active ModerateUnited States, China, Croatia, France, India, Japan, Israel, Taiwan, Brazil, Serbia, Greece, Hungary, Argentina, Italy, Poland, Czechia, Colombia, Lithuania, Latvia, Ukraine, South Africa, Portugal, Mexico, Canada, Slovakia, Turkey (Türkiye) and more
-
Odyssey TherapeuticsRecruitingUlcerative Colitis (UC) | UC - Ulcerative ColitisAustralia, Austria, Jordan, Poland, Ukraine, New Zealand, Canada, Czechia, Lithuania, Moldova
-
Assistance Publique - Hôpitaux de ParisURC-CIC Paris Descartes Necker Cochin; MRSU 938 - Research Center of Saint...Not yet recruitingPediatric Ulcerative Colitis in RemissionFrance
-
Ferring PharmaceuticalsCompletedActive Ulcerative Colitis | Remission of Ulcerative ColitisCanada
-
Academisch Medisch Centrum - Universiteit van Amsterdam...University Medical Center Groningen; UMC UtrechtCompletedUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis AcuteNetherlands
-
Alexion Pharmaceuticals, Inc.Immune PharmaceuticalsTerminatedUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateIsrael
-
Palatin Technologies, IncActive, not recruitingUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis Acute | UlcerativeUnited States
-
Theravance BiopharmaCompletedUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateUnited States, Georgia, Moldova, Republic of, Romania
-
Merck Sharp & Dohme LLCRecruitingUlcerative Colitis | Colitis UlcerativeUnited States
Clinical Trials on Colonoscopy with Indigo-Carmine chromoendoscopy
-
Karolinska University HospitalUnknownLymphocytic Colitis | Collagenous Colitis | Chronic DiarrhoeaSweden
-
Mayo ClinicCompletedColonic PolypsUnited States
-
Hospital Universitario de MóstolesCompletedColonic Polyp | Colonic Neoplasms | Colonic Cancer
-
King's College Hospital NHS TrustCompletedInflammatory Bowel DiseaseUnited Kingdom
-
Shandong UniversityRecruitingColorectal Neoplasms | Colonic Polyps | Adenomatous Polyps | Adenoma Detection Rate | ChromoendoscopyChina
-
Weill Medical College of Cornell UniversityCompletedBrain Tumors With Ill-defined MarginsUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedUlcerative Colitis | ChromoendoscopyNetherlands
-
Walter BrunnerCompletedRectal NeoplasmsSwitzerland
-
The Leeds Teaching Hospitals NHS TrustUnknown
-
Changhai HospitalThe First Affiliated Hospital of Nanchang University; The Second Hospital of... and other collaboratorsNot yet recruitingSessile Serrated LesionChina